NUEVOS DERIVADOS NAFTALENICOS, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN

• Main Authors: YOUS, SAID, DELAGRANGE, PHILIPPE, BERTHELOT, PASCAL, PERES, BASILE, SABAOUNI, AHMED, SPEDDING, MICHAEL
• Format: Patent
• Language: Spanish
• Published: 08.03.2010
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Compuesto de fórmula (I) **(Ver fórmula)** o N-[3-hidroxi-2-(7-metoxi-1-naftil)propil]propanoamida sus enantiómeros, así como sus sales de adición de una base farmacéuticamente aceptable. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide (I), its enantiomers and base addition salts, are new. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide of formula (I), its enantiomers and base addition salts, are new. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Antimigraine; Neuroprotective; Cerebroprotective; Contraceptive; Endocrine-Gen; Immunomodulator; Cytostatic. MECHANISM OF ACTION : Melatonin receptor binder. The ability of (I) to bind with melatonin was tested. The results showed that N-[3-hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide exhibited an inhibition constant value of 1.4 nM and 3.2 nM to bind with melatonin receptors MT 1 and MT 2, respectively.